趋化因子CCL5在涎腺腺样囊性癌患者肿瘤组织和血清中的表达及临床意义
|
摘要
目的研究趋化因子CCL5在涎腺腺样囊性癌(salivaryadenoid cystic carcinoma,SACC)患者肿瘤组织和血清中的表达及临床意义。方法收集SACC患者76例术前血清样本、手术中肿瘤组织和癌旁腮腺组织病理切片,32例体检健康对照者血清样品。应用免疫组织化学法检测CCL5及其受体CCR5蛋白在SACC肿瘤和癌旁组织中的表达,ELISA法检测血清CCL5水平。结果 SACC肿瘤组织中CCL5和CCR5表达水平明显高于癌旁组织,且差异均具有统计学意义(P <0. 001)。观察组血清中CCL5的表达量为(8. 43±1. 36) ng/ml,显著高于对照组的(1. 11±0. 78) ng/ml(P <0. 001)。不同肿瘤发生部位的患者血清CCL5水平间差异无统计学意义(P> 0. 05);不同组织学分型、淋巴结转移情况、肿瘤TMN分期的患者间血清CCL5水平差异具有统计学意义(P <0. 05)。血清CCL5水平与肿瘤组织中CCL5蛋白表达呈正相关(γ=0. 742,P <0. 001),与肿瘤细胞中CCR5蛋白表达亦呈正相关(γ=0. 799,P <0. 001)。结论趋化因子CCL5的异常表达可能在SACC的发生与发展过程中起重要作用,并有可能作为临床上SACC早期监测指标。
Objective To study the expression and clinical significance of chemokine CCL5 in tumor tissue and serum of salivary adenoid cystic carcinoma. Methods The serum samples of 76 patients with SACCOur hospital,were collected. Detection of CCL5 and its receptor CCR5 protein in SACC tumor and paracancerous tumor by immunohistochemical method The level of serum CCL5 was detected by Elisa. Results The expression levels of CCL5 and CCR5 in the tumor tissues were significantly higher than those of the paracancerous tissues( P < 0. 001). The expression of CCL5 in serum of the observation group was significantly higher than that of the control group( 8. 43 ± 1. 36) ng/ml vs( 1. 11 ± 0. 78) ng/ml vs( 1. 11 ± 0. 78) ng/ml,P < 0. 05. There was no significant difference in serum CCL5 levels among patients with different tumor sites( P > 0. 05). There was significant difference in serum CCL5 level between patients with TMN staging( P < 0. 05). The level of serum CCL5 was positively correlated with the expression of CCL5 protein in tumor tissues( P < 0. 742,P < 0. 05). The expression of CCR5 protein was positively correlated with the expression of CCR5 protein in tumor cells( P < 0. 05,P < 0. 05,P < 0. 05). Conclusion The abnormal expression of chemokine CCL5 may play an important role in the occurrence and development of SACC,and may be used as an early clinical monitoring index for SACC.
Objective To study the expression and clinical significance of chemokine CCL5 in tumor tissue and serum of salivary adenoid cystic carcinoma. Methods The serum samples of 76 patients with SACCOur hospital,were collected. Detection of CCL5 and its receptor CCR5 protein in SACC tumor and paracancerous tumor by immunohistochemical method The level of serum CCL5 was detected by Elisa. Results The expression levels of CCL5 and CCR5 in the tumor tissues were significantly higher than those of the paracancerous tissues( P < 0. 001). The expression of CCL5 in serum of the observation group was significantly higher than that of the control group( 8. 43 ± 1. 36) ng/ml vs( 1. 11 ± 0. 78) ng/ml vs( 1. 11 ± 0. 78) ng/ml,P < 0. 05. There was no significant difference in serum CCL5 levels among patients with different tumor sites( P > 0. 05). There was significant difference in serum CCL5 level between patients with TMN staging( P < 0. 05). The level of serum CCL5 was positively correlated with the expression of CCL5 protein in tumor tissues( P < 0. 742,P < 0. 05). The expression of CCR5 protein was positively correlated with the expression of CCR5 protein in tumor cells( P < 0. 05,P < 0. 05,P < 0. 05). Conclusion The abnormal expression of chemokine CCL5 may play an important role in the occurrence and development of SACC,and may be used as an early clinical monitoring index for SACC.
引文
[1]柏书博,王良,吴刚.涎腺腺样囊性癌增殖、侵袭及转移相关基因研究进展[J].临床军医杂志,2016,44(12):1310-1312+1315.
[2]王愿林,程莉.基质金属蛋白酶9在涎腺腺样囊性癌患者血清中的表达与意义[J].临床和实验医学杂志,2015,14(12):987-990.
[3]王蕊,李立恒,谢丽娟,等.涎腺腺样囊性癌患者生存及预后的独立影响因素分析[J].实用癌症杂志,2016,31(8):1342-1344.
[4]魏承彬,王晓峰,赵丹.涎腺腺样囊性癌增殖、侵袭及转移相关信号通路的研究进展[J].肿瘤研究与临床,2014,26(4):283-286.
[5]朱永云,李娟娟,赵迎春,等.乳腺癌CC类趋化因子5表达与上皮间质转化的相关性及其意义[J].中国肿瘤,2016,25(4):314-318.
[6]黄尧垚,汤成春.趋化因子及其受体与冠心病关系研究进展[J].现代医学,2010,38(3):312-316.
[7]李添翼,申志远.CCL5/CCR5生物轴在涎腺腺样囊性癌细胞嗜神经侵袭中的作用[J].华西口腔医学杂志,2017,35(5):479-483.
[8]Beesley MF,Mclaren KM.Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules[J].Histopathology,2002,41(3):236-243.
[9]刘修莉,郝婷婷,李云霄,等.Th1/Th2细胞与肿瘤微环境[J].实用癌症杂志,2015,30(9):1415-1417.
[10]丁海霞,赵连梅,单保恩.肿瘤相关巨噬细胞和CCL5在胃癌中的表达及其相关性研究[J].中国免疫学杂志,2016,32(1):74-78.
[11]丁海霞,赵连梅,崔雯萱,等.CCL5在胃癌患者肿瘤组织和血清中的表达及临床意义[J].中国免疫学杂志,2016,32(5):707-710.
[12]朱永云,李娟娟,陈创,等.不同激素受体状态乳腺癌趋化因子CCL5的表达及临床意义[J].中华乳腺病杂志(电子版),2016,10(2):71-75.
[13]梁亮,邓骞,聂治军,等.趋化因子CCL5表达与肾透明细胞癌病理特征及预后的相关性研究[J].现代肿瘤医学,2018,26(3):405-408.
[14]Aldinucci D,Colombatti A.The inflammatory chemokine C-CL5 and cancer progression[J].Mediators Inflamm,2014,2014:292376.
[15]Tan MC,Goedegebuure PS,Belt BA,et al.Disruption of C-CR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer[J].J Immunol,2009,182(3):1746-1755.
[16]Zhang Y,Meng FY,Li WL,et al.Association of chemotactic factor receptor 5 gene with breast cancer[J].Genet Mol Res,2013,12(4):5289-5300.
[2]王愿林,程莉.基质金属蛋白酶9在涎腺腺样囊性癌患者血清中的表达与意义[J].临床和实验医学杂志,2015,14(12):987-990.
[3]王蕊,李立恒,谢丽娟,等.涎腺腺样囊性癌患者生存及预后的独立影响因素分析[J].实用癌症杂志,2016,31(8):1342-1344.
[4]魏承彬,王晓峰,赵丹.涎腺腺样囊性癌增殖、侵袭及转移相关信号通路的研究进展[J].肿瘤研究与临床,2014,26(4):283-286.
[5]朱永云,李娟娟,赵迎春,等.乳腺癌CC类趋化因子5表达与上皮间质转化的相关性及其意义[J].中国肿瘤,2016,25(4):314-318.
[6]黄尧垚,汤成春.趋化因子及其受体与冠心病关系研究进展[J].现代医学,2010,38(3):312-316.
[7]李添翼,申志远.CCL5/CCR5生物轴在涎腺腺样囊性癌细胞嗜神经侵袭中的作用[J].华西口腔医学杂志,2017,35(5):479-483.
[8]Beesley MF,Mclaren KM.Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules[J].Histopathology,2002,41(3):236-243.
[9]刘修莉,郝婷婷,李云霄,等.Th1/Th2细胞与肿瘤微环境[J].实用癌症杂志,2015,30(9):1415-1417.
[10]丁海霞,赵连梅,单保恩.肿瘤相关巨噬细胞和CCL5在胃癌中的表达及其相关性研究[J].中国免疫学杂志,2016,32(1):74-78.
[11]丁海霞,赵连梅,崔雯萱,等.CCL5在胃癌患者肿瘤组织和血清中的表达及临床意义[J].中国免疫学杂志,2016,32(5):707-710.
[12]朱永云,李娟娟,陈创,等.不同激素受体状态乳腺癌趋化因子CCL5的表达及临床意义[J].中华乳腺病杂志(电子版),2016,10(2):71-75.
[13]梁亮,邓骞,聂治军,等.趋化因子CCL5表达与肾透明细胞癌病理特征及预后的相关性研究[J].现代肿瘤医学,2018,26(3):405-408.
[14]Aldinucci D,Colombatti A.The inflammatory chemokine C-CL5 and cancer progression[J].Mediators Inflamm,2014,2014:292376.
[15]Tan MC,Goedegebuure PS,Belt BA,et al.Disruption of C-CR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer[J].J Immunol,2009,182(3):1746-1755.
[16]Zhang Y,Meng FY,Li WL,et al.Association of chemotactic factor receptor 5 gene with breast cancer[J].Genet Mol Res,2013,12(4):5289-5300.